Nathwani D, Davey P
Infection and Immunodeficiency Service, King's Cross Hospital, Dundee.
BMJ. 1996 Dec 14;313(7071):1541-3. doi: 10.1136/bmj.313.7071.1541.
The NHS Executive is keen to promote "hospital at home" services in Britain, as part of its philosophy of keeping more care in the community and also to relieve the increasing demand for hospital beds. One such service is the provision of intravenous antimicrobial therapy in the community. Yet, compared with the United States, where home or outpatient intravenous antimicrobial therapy programmes are well developed, experience in Britain and Europe is limited, reflecting a difference in cultural attitudes and healthcare structures between the two continents. Only a few units in Britain currently run home intravenous antimicrobial therapy programmes, and several issues need to be addressed if more treatment is to be provided outside hospital. These include an assessment of the need for community intravenous antibiotic treatment and which patient groups many benefit. The main motive for community intravenous treatment should be better patient care and not simply a reduction in healthcare costs. At present the pace of change is being set by a few clinical enthusiasts and by commercial organisations, whereas the NHS deserves a more organised strategy for purchasing treatment with intravenous antibiotics in the community.
英国国民医疗服务体系(NHS)行政部门热衷于在英国推广“居家医院”服务,这是其让更多护理在社区进行理念的一部分,同时也是为了缓解对医院病床日益增长的需求。其中一项服务就是在社区提供静脉抗菌治疗。然而,与美国相比,美国的居家或门诊静脉抗菌治疗项目发展良好,而英国和欧洲在这方面的经验有限,这反映出两大洲在文化态度和医疗结构上的差异。目前英国只有少数机构开展居家静脉抗菌治疗项目,如果要在医院外提供更多此类治疗,还需要解决几个问题。这些问题包括评估社区静脉抗生素治疗的需求以及哪些患者群体可能从中受益。社区静脉治疗的主要动机应该是更好地护理患者,而不仅仅是降低医疗成本。目前,变革的步伐由一些临床热心人士和商业组织推动,而NHS应该制定一个更有条理的策略,用于在社区购买静脉抗生素治疗服务。